Research programme: growth hormone-releasing hormone antagonists - Biscayne Pharmaceuticals

Drug Profile

Research programme: growth hormone-releasing hormone antagonists - Biscayne Pharmaceuticals

Alternative Names: BIS-1062; GHRH antagonists - Biscayne

Latest Information Update: 13 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Miami
  • Developer Biscayne Pharmaceuticals
  • Class Hypothalamic hormones
  • Mechanism of Action Growth hormone releasing factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 13 Oct 2014 Preclinical trials in Ovarian cancer in USA (Parenteral)
  • 03 Sep 2014 Preclinical trials in Breast cancer in USA (Parenteral)
  • 21 May 2014 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top